Vectra score is an objective and more accurate predictor of radiographic progression (RP) when compared with other disease activity measures1-3
Patients with low or moderate Vectra scores may benefit from non-biologic therapy, including combination DMARD therapy, without increasing risk of RP for periods of time throughout the course of their disease4,5
Patients with high scores should consider initiation, titration in dose, or a change of biologic DMARD therapy, because of increased risk of RP4,5
Vectra-enhanced care results in savings6
Fact Sheets and Product Info:
Find more Myriad info as well as links to National Institutes of Health rheumatoid arthritis resources.
About Rheumatoid Arthritis:
Rheumatoid arthritis (RA) has high prevalence (1.5 million adult cases in the US) and high median annual healthcare costs ($4,677 for RA patients vs. $1,229 for non-RA patients).
RA can be treated with two types of disease modifying anti-rheumatic drugs (DMARDs): traditional non-biologic DMARDs (appropriate with low RA disease activity) and biologic DMARDs (appropriate with high RA disease activity). Biologic DMARDs lead to decreased mean disease activity, hospitalization, sick leave, and work-related disability in RA patients, but cause significant increase in treatment costs.
Although significant clinical advances have been made in RA over the last two decades, challenges remain in optimizing treatment decisions, which add unnecessary healthcare costs and increase burden on payers. For the most part, clinicians do not use formal measures of disease activity and when they do, the measures used are made up of subjective components, such as the DAS28, CDAI, SDAI, and RAPID3*, and measure on-going efficacy of different therapy selections.
There is a need for objective measures of disease activity that provide a comprehensive understanding of disease progression at the patient level, taking into account RA disease heterogeneity, while minimizing the impact on the physician’s time. Vectra® fulfills this unmet need by combining multiple serum biomarkers into a single score that can help physicians characterize disease activity in patients, assess response to treatment, identify risk of joint damage, and potentially guide second line treatment after methotrexate and inform tapering decisions for patients in stable remission.+ Use of Vectra may help avoid unnecessary drug exposure and expenditure, potentially creating overall savings for physicians, patients, and payers.
1. Curtis JR, et al. Curr Med Res Opin. 2019; 35(9):1483-1493.
2. Curtis JR, et al. Rheumatology. 2019; 58(5): 874-883.
3. Myriad data on file.
4, 5. Adapted from Hambardzumyan K, et al. Arthritis Rheumatol. 2015;67(suppl 10). http://acrabstracts.org/abstract/the-multi-biomarker-disease-activity-score-in-methotrexate-incomplete-responders-predicts-clinical-responses-to-non-biological-versus-biological-therapy-in-early-ra/. Accessed May 6, 2016 and Hambardzumyan K, et al. RMD Open. 2016;2:e000197. doi:10.1136/rmdopen-2015-000197.
6. Kroger Prescription Plans and Myriad data on file Sep 2020.
* DAS28: 28-Joint Disease Activity Score, CDAI: Clinical Disease Activity Index, SDAI: Simplified Disease Activity Index, RAPID3: Routine Assessment of Patient Index Data.
+ This test is not intended or validated to diagnose RA or to predict response to a specific drug.